---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-011851"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2025-02-12T23:59:59+00:00"
generated_at: "2026-05-26T22:57:01.932264+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Replimune Q3 net loss $66.3M; FDA accepts RP1 BLA with priority review, PDUFA July 22

## Summary
- FDA accepted BLA for RP1+nivolumab in advanced melanoma with Priority Review; PDUFA date July 22, 2025.
- Net loss $66.3M for fiscal Q3 2025, up from $51.1M in Q3 2024; R&D expense $48.0M.
- Cash & investments $536.5M as of Dec 31, 2024, expected to fund operations into Q4 2026.
- Public offering raised ~$156M net to support RPx development and potential commercial launch.
- First patients enrolled in RP2 registration-directed trial for uveal melanoma and Phase 2 HCC trial.

## SEC filing metadata
- accession: 0001104659-25-011851
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2025-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465925011851/0001104659-25-011851-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465925011851/tm256243d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-011851
- JSON: https://secwatch.observer/filing/0001104659-25-011851.json
- Plain text: https://secwatch.observer/filing/0001104659-25-011851.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.